Article
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
BMC cancer - 10 Jan 2014
Ihle Michaela Angelika, Fassunke Jana, König Katharina, Grünewald Inga, Schlaak Max, Kreuzberg Nicole, Tietze Lothar, Schildhaus Hans-Ulrich, Büttner Reinhard, Merkelbach-Bruse Sabine
Abstract excerpt
BACKGROUND: The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600 (p.V600E) or a substitution of valine to leucine (p.V600K) in BRAF show complete or partial response. Therefore, the precise identification of the underlying somatic mutations is essential. Herein, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.